Keywords: UK, NICE< GlaxoSmithKline, Revolade, Neuroscrine, Antideprssant, GSK561679, Fails in Phase II

UK’s NICE turns down GlaxoSmithKline’s Revolade, as drugmaker and Neurocrine’s antidepressant fails in Ph II

Article | 15 September 2010

Print This

UK pharmaceutical giant GlaxoSmithKline (LSE: GSK) sustained a double dose of bad news yesterday, after the UK’ drugs watchdog ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in